Floatz logo

Rly-8161

NRAS G12V

Relay Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the NRAS G12V cohort.

Asset / SponsorPhaseRating
Eli-002 7P
Elicio Therapeutics
Phase 1/2CCC

Same molecule, other indications

Rly-8161 is also rated in:

NRAS G12DDormant
CC
Indicative ·
43 / 100
View asset →
NRAS MutationDormant
NR
Indicative ·
/ 100
View asset →
Advanced NRAS-Mutant Solid TumorsDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →